Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01976728 · ClinicalTrials.gov registry record · Phase 3
LutrePulse Hypogonadotropic Hypogonadism
A Phase 3 study of Primary Amenorrhea With Hypogonadotropic Hypogonadism, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 39
- Enrollment target
- 20
- Study locations
NCT01976728 is a Phase 3 study of Primary Amenorrhea With Hypogonadotropic Hypogonadism that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 39 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT01976728, a Phase 3 study of Primary Amenorrhea With Hypogonadotropic Hypogonadism, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 39 participants
- Enrollment target
- 20
- Study locations
Study Summary
To compare the ovulation rate in women with primary amenorrhea with hypogonadotropic hypogonadism following pulsatile gonadotropin-releasing hormone (GnRH) treatment using the OmniPod pump versus placebo
Conditions Studied
Interventions
- DRUG Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump
- DRUG Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump
- DRUG Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump
- DRUG Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)
Study Locations (20)
North Carolina
- Carolinas HealthCare System - Charlotte
- Lyndhurst Clinical Research - Winston-Salem
- Wake Forest University Health Sciences - Winston-Salem
Florida
- Women's Medical Research Group, LLC - Clearwater
- Center for Reproductive Medicine - Orlando
Ohio
- Institute for Reproductive Health - Cincinnati
- University of Cincinnati Physicians - Cincinnati
Arizona
- Fertility Treatment Center - Tempe
California
- Center for Reproductive Health UCSF - San Francisco
Colorado
- University of Colorado School of Medicine - Aurora
Delaware
- Reproductive Associates of Delaware - Newark
District of Columbia
- Columbia Fertility Associates - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2014-04-01 |
| Est. Completion | 2018-02-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01976728
The ClinicalTrials.gov registry entry for NCT01976728 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Amenorrhea With Hypogonadotropic Hypogonadism appearing as the primary indexed condition, and to 4 interventions - of which Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump is the first listed.
NCT01976728 reports 20 study locations spanning 16 distinct geographic areas - top geographies include North Carolina, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT01976728 about?
NCT01976728 is a clinical study titled "LutrePulse Hypogonadotropic Hypogonadism". To compare the ovulation rate in women with primary amenorrhea with hypogonadotropic hypogonadism following pulsatile gonadotropin-releasing hormone (GnRH) treatment using the OmniPod pump versus placebo
What is the current status of trial NCT01976728?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 39 participants. The study started on 2014-04-01. Estimated completion is 2018-02-23.
What conditions does trial NCT01976728 study?
This clinical trial studies the following conditions: Primary Amenorrhea With Hypogonadotropic Hypogonadism.
What interventions are being tested in trial NCT01976728?
The interventions under investigation include: Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump (DRUG), Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump (DRUG), Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump (DRUG), Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump) (DRUG).
Who is sponsoring clinical trial NCT01976728?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01976728 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.